On December 10, 2025, Aytu BioPharma, Inc. held its 2026 annual meeting where 60% of shares voted, electing all incumbent directors and approving the appointment of Grant Thornton LLP as the new auditor for the fiscal year ending June 30, 2026. The stockholders also supported the advisory vote on executive compensation with significant majority.